The 100,000 sq ft scheme is being built for Cambridge Medipark Ltd and will be occupied by Abcam, a supplier of life science research tools, which has signed a 20-year lease. The premises will consist of a three-storey laboratory building and a four-storey office building, connected by an atrium link.
Works begin on site this month, March 2017, with a scheduled completion date of late 2018.
The new site will allow Abcam to combine its three current facilities in Cambridge into one new global headquarters.
It will be the first building on the 20-acre phase two expansion of Cambridge Biomedical Campus since planning consent was granted at the end of last year to meet demand from prospective occupiers.
Elsewhere on the campus Kier is building Project Capella, a £79m laboratory development for the University of Cambridge. [See our previous report here.]
Peter Young, Kier executive director, said: “This is another prestigious win for Kier in the biotech sector, building on our sector-leading expertise, as well as reaffirming our track record across Cambridge. Kier has extensive experience delivering specialist research facilities, and we are proud to be playing a key role in developing Cambridge Biomedical Campus – a world-renowned centre of clinical and healthcare excellence.”